Effects of interleukin 2 therapy in patients with common variable immunodeficiency (CVID).
Rump
J A
JA
Dept. of Rheumatology, University of Freiburg, FRG.
Jahreis
A
A
Schlesier
M
M
Stecher
S
S
Dräger
R
R
Struff
W G
WG
Peter
H H
HH
D017074:Common Variable Immunodeficiency / Q000145:classification / Q000276:immunology / Q000628:therapy*; D004311:Double-Blind Method; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000096:biosynthesis; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000096:biosynthesis / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008213:Lymphocyte Activation; D016853:Muromonab-CD3 / Q000494:pharmacology; D011043:Pokeweed Mitogens / Q000494:pharmacology; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D013745:Tetanus Toxoid / Q000494:pharmacology
D007074:Immunoglobulin G; D007075:Immunoglobulin M; D016756:Immunoglobulins, Intravenous; D007376:Interleukin-2; D016853:Muromonab-CD3; D011043:Pokeweed Mitogens; D015375:Receptors, Interleukin-2; D013745:Tetanus Toxoid